Literature DB >> 25755441

An Update on Drug-induced Liver Injury.

Harshad Devarbhavi1.   

Abstract

Idiosyncratic drug-induced liver injury (DILI) is an important cause of morbidity and mortality following drugs taken in therapeutic doses. Hepatotoxicity is a leading cause of attrition in drug development, or withdrawal or restricted use after marketing. No age is exempt although adults and the elderly are at increased risk. DILI spans the entire spectrum ranging from asymptomatic elevation in transaminases to severe disease such as acute hepatitis leading to acute liver failure. The liver specific Roussel Uclaf Causality Assessment Method is the most validated and extensively used for determining the likelihood that an implicated drug caused DILI. Asymptomatic elevation in liver tests must be differentiated from adaptation. Drugs producing DILI have a signature pattern although no single pattern is characteristic. Antimicrobial and central nervous system agents including antiepileptic drugs are the leading causes of DILI worldwide. In the absence of a diagnostic test or a biomarker, the diagnosis rests on the evidence of absence of competing causes such as acute viral hepatitis, autoimmune hepatitis and others. Recent studies show that antituberculosis drugs given for active or latent disease are still a major cause of drug-induced liver injury in India and the West respectively. Presence of jaundice signifies a severe disease and entails a worse outcome. The pathogenesis is unclear and is due to a mix of host, drug metabolite and environmental factors. Research has evolved from incriminating candidate genes to genome wide analysis studies. Immediate cessation of the drug is key to prevent or minimize progressive damage. Treatment is largely supportive. N-acetylcysteine is the antidote for paracetamol toxicity. Carnitine has been tried in valproate injury whereas steroids and ursodeoxycholic acid may be used in DILI associated with hypersensitivity or cholestatic features respectively. This article provides an overview of the epidemiology, the patterns of hepatotoxicity, the pathogenesis and associated risk factors besides its clinical management.

Entities:  

Keywords:  ADR, adverse drug reaction; AED, antiepileptic drugs; BSEP, bile salt export pump; CDS, clinical diagnostic scale; CIOMS, Council for International Organization of Medical Sciences; CXR, constitutive androstane receptor; DIAIH, drug-induced autoimmune hepatitis; DIALF, drug-induced acute liver failure; DILI; DILI, idiosyncratic drug-induced liver injury; FXR, farnesoid X receptor; GWAS, genome wide association studies; HBV, hepatitis B virus; HIV, human immunodeficiency virus; INH, isoniazid; LPS, lipopolysaccharide; MHC, major histocompatibility complex; MRP, multi-drug resistance proteins; NAC, N-acetylcysteine; NAPQI, N-acetyl-p-benzoquinone imine; NRH, nodular regenerative hyperplasia; PXR, pregnane X receptor; PZA, pyrazinamide; RIF, rifampicin; RUCAM, Roussel Uclaf Causality Assessment Method; TEN, toxic epidermal necrolysis; UDCA, ursodeoxycholic acid; causality; drug-induced; hepatotoxicity; liver injury

Year:  2012        PMID: 25755441      PMCID: PMC3940315          DOI: 10.1016/j.jceh.2012.05.002

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  104 in total

Review 1.  Immunology of the healthy liver: old questions and new insights.

Authors:  W Z Mehal; F Azzaroli; I N Crispe
Journal:  Gastroenterology       Date:  2001-01       Impact factor: 22.682

2.  Vanishing bile duct syndrome: amoxicillin-clavulanic acid associated intra-hepatic cholestasis responsive to ursodeoxycholic acid.

Authors:  L A Smith; J R A Ignacio; M P Winesett; G C Kaiser; A G Lacson; E Gilbert-Barness; R P González-Peralta; M J Wilsey
Journal:  J Pediatr Gastroenterol Nutr       Date:  2005-10       Impact factor: 2.839

3.  Antibiotic therapy: a major cause of drug-induced jaundice in southwest England.

Authors:  Syed H Hussaini; Ciara S O'Brien; Edward J Despott; Harry R Dalton
Journal:  Eur J Gastroenterol Hepatol       Date:  2007-01       Impact factor: 2.566

4.  Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes.

Authors:  F Lakehal; P M Dansette; L Becquemont; E Lasnier; R Delelo; P Balladur; R Poupon; P H Beaune; C Housset
Journal:  Chem Res Toxicol       Date:  2001-06       Impact factor: 3.739

5.  International drug monitoring: the role of national centres. Report of a WHO meeting.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1972

6.  Identification of a reactive metabolite of terbinafine: insights into terbinafine-induced hepatotoxicity.

Authors:  S L Iverson; J P Uetrecht
Journal:  Chem Res Toxicol       Date:  2001-02       Impact factor: 3.739

7.  Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury.

Authors:  Timothy J Davern; Naga Chalasani; Robert J Fontana; Paul H Hayashi; Petr Protiva; David E Kleiner; Ronald E Engle; Hanh Nguyen; Suzanne U Emerson; Robert H Purcell; Hans L Tillmann; Jiezhun Gu; Jose Serrano; Jay H Hoofnagle
Journal:  Gastroenterology       Date:  2011-08-16       Impact factor: 22.682

Review 8.  Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.

Authors:  T N Kakuda
Journal:  Clin Ther       Date:  2000-06       Impact factor: 3.393

Review 9.  Antiepileptic drug-induced hypersensitivity syndrome reactions.

Authors:  Norberto Krivoy; Masud Taer; Manuela G Neuman
Journal:  Curr Drug Saf       Date:  2006-08

10.  Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?

Authors:  G P Aithal; B Haugk; S Das; T Card; A D Burt; C O Record
Journal:  Aliment Pharmacol Ther       Date:  2004-02-15       Impact factor: 8.171

View more
  30 in total

1.  Answers to multiple choice questions.

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2012-12

2.  Factors associated with adverse drug reactions in older inpatients in teaching hospital.

Authors:  Tácita Pires de Figueiredo; Ronara Camila de Souza Groia; Soraya Coelho Costa Barroso; Mariana Martins Gonzaga do Nascimento; Adriano Max Moreira Reis
Journal:  Int J Clin Pharm       Date:  2017-05-02

3.  Protective effects of melatonin and L-carnitine against methotrexate-induced toxicity in isolated rat hepatocytes.

Authors:  Lamiaa A Khatab; Ihab T Abdel-Raheem; Asser I Ghoneim
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-11-25       Impact factor: 3.000

4.  In vitro Evaluation of Isoniazid Derivatives as Potential Agents Against Drug-Resistant Tuberculosis.

Authors:  Joaquim Trigo Marquês; Catarina Frazão De Faria; Marina Reis; Diana Machado; Susana Santos; Maria da Soledade Santos; Miguel Viveiros; Filomena Martins; Rodrigo F M De Almeida
Journal:  Front Pharmacol       Date:  2022-05-04       Impact factor: 5.988

Review 5.  The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment.

Authors:  Marta Moreno-Torres; Guillermo Quintás; José V Castell
Journal:  Metabolites       Date:  2022-06-19

6.  Ischaemic Markers in Acute Hepatic Injury.

Authors:  Suchismita Panda; Sushanta Kumar Jena; Rachita Nanda; Manaswini Mangaraj; Parsuram Nayak
Journal:  J Clin Diagn Res       Date:  2016-04-01

7.  Outcomes and Predictors of Mortality in Patients With Drug-Induced Liver Injury at a Tertiary Hospital in South India: A Single-Centre Experience.

Authors:  Nanjegowda Sunil Kumar; Bhavith Remalayam; Varghese Thomas; Thazhath M Ramachandran; Kandiyil Sunil Kumar
Journal:  J Clin Exp Hepatol       Date:  2020-08-20

8.  Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19.

Authors:  Terry Cheuk-Fung Yip; Vincent Wai-Sun Wong; Grace Chung-Yan Lui; Viola Chi-Ying Chow; Yee-Kit Tse; Vicki Wing-Ki Hui; Lilian Yan Liang; Henry Lik-Yuen Chan; David Shu-Cheong Hui; Grace Lai-Hung Wong
Journal:  Hepatology       Date:  2021-06-21       Impact factor: 17.298

9.  CSH guidelines for the diagnosis and treatment of drug-induced liver injury.

Authors:  Yue-Cheng Yu; Yi-Min Mao; Cheng-Wei Chen; Jin-Jun Chen; Jun Chen; Wen-Ming Cong; Yang Ding; Zhong-Ping Duan; Qing-Chun Fu; Xiao-Yan Guo; Peng Hu; Xi-Qi Hu; Ji-Dong Jia; Rong-Tao Lai; Dong-Liang Li; Ying-Xia Liu; Lun-Gen Lu; Shi-Wu Ma; Xiong Ma; Yue-Min Nan; Hong Ren; Tao Shen; Hao Wang; Ji-Yao Wang; Tai-Ling Wang; Xiao-Jin Wang; Lai Wei; Qing Xie; Wen Xie; Chang-Qing Yang; Dong-Liang Yang; Yan-Yan Yu; Min-de Zeng; Li Zhang; Xin-Yan Zhao; Hui Zhuang
Journal:  Hepatol Int       Date:  2017-04-12       Impact factor: 6.047

10.  Fimasartan-induced liver injury in a patient with no adverse reactions on other types of angiotensin II receptor blockers: A case report.

Authors:  Dae Hwa Park; Gee Young Yun; Hyuk Soo Eun; Jong Seok Joo; Ju Seok Kim; Sun Hyung Kang; Hee Seok Moon; Eaum Seok Lee; Byung Seok Lee; Kyung Hee Kim; Seok Hyun Kim
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.